Recent Publications

NanoGroup financed 7.5 million zł new shares of Auxilius Pharma in a financing round of this company with a total value of 15 million zł – reported NanoGroup. In this way, NanoGroup expanded its portfolio to the Value Added Medications (VAM) segment.

"The funds obtained through this important process for the industry will enable Auxilius Pharma SA – the pioneer among Polish companies in the value-added medications field – to conduct a clinical trial for the improved medicine for chronic stable angina pectoris, opening the way for partnering with a priority on the American market," the press release reported.

Auxilius Pharma is a private pharmaceutical company that started operating in 2019. Auxilius focuses on value-added medications and brings innovation to high-demand areas where patients with conditions such as chronic stable angina pectoris can have a positive impact on public health. Auxilius Pharma's research and development strategy is driven by patients' need for affordable medicines that help manage their chronic conditions in the U.S. and other major markets.

"Auxilius' most important project is AUX-001: a medicine for chronic stable angina pectoris. The drug is based on a proven mechanism of action and a safe profile. It relieves symptoms, reduces the risk of cardiovascular events and hospitalizations, and the modern once-daily formula makes treatment more convenient and potentially more effective," the statement said.

It is reported that the company will file an application with the FDA to allow preparing AUX-001 for commercialization in the U.S. in 2028.

"We plan to conduct the next-phase clinical trial in 2026. After its successful completion, only the third phase remains, which will significantly increase the attractiveness of our project for future partners as it approaches market entry. It is possible that we will already sign a partnering agreement in the first half of 2027 with a player that has a strong presence in the cardiovascular medication market in the U.S. Many companies we speak with are looking for third-phase-stage projects to quickly complement their pipelines," said Jędrzej Litwiniuk, CEO of Auxilius Pharma, quoted in the press release.

Part of the funds received – 7.5 million zł – comes from the Series D share purchase agreement executed by the ffVC fund on behalf of NanoGroup. The shares purchased by the fund carry preferred status. In the agreement signed between NanoGroup and the ffVC fund, a side letter was attached that governs the oversight rules and the exercise of rights arising from this preferred investment status. The remaining 7.5 million zł will be provided by the NCBR Investment Fund ASI as a co-investment with the ffVC fund, as noted in the announcement. (PAP Biznes)

About Auxilius Pharma

Auxilius Pharma is a private pharmaceutical company that started operating in 2019. Auxilius focuses on value-added medications and brings innovation to high-demand areas where patients with conditions such as chronic stable angina pectoris can have a positive impact on public health. Auxilius Pharma's research and development strategy is driven by patients' need for affordable medicines that help manage their chronic conditions in the U.S. and other major markets.